Summary & Overview
CPT 81348: SRSF2 Gene Mutation Detection, Targeted Molecular Test
CPT code 81348 represents a targeted molecular diagnostic assay for detecting common variants in the SRSF2 gene (e.g., P95H, P95L) from patient specimens such as blood. These variants are clinically relevant in hematologic malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), where identification of SRSF2 alterations can inform diagnostic classification, prognostic assessment, and care planning. Nationally, accurate coding and coverage for molecular assays like CPT code 81348 matter because they affect access to precision diagnostics, laboratory workflows, and payer reimbursement policies for oncology-related genetic testing.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for SRSF2 testing, typical sites of service and service type, and the payer landscape addressed in the publication. The report summarizes common modifiers for lab services, highlights typical billing considerations, and outlines where to find relevant policy language or local coverage determinations. Data not available in the input will be noted as such; the document focuses on practical coding identification and clinical relevance rather than local pricing or state-specific policies.
Billing Code Overview
CPT code 81348 describes a laboratory molecular diagnostic test that detects common alterations in the SRSF2 (serine and arginine–rich splicing factor 2) gene, such as P95H and P95L, performed on a patient specimen (for example, blood). The test identifies pathogenic or likely pathogenic variants that may be associated with hematologic conditions such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Service type: Molecular pathology / targeted gene sequencing
Typical site of service: Clinical laboratory or hospital-based laboratory (specimen collected at outpatient clinic, hospital, or phlebotomy site; analysis performed in a laboratory setting)
Clinical & Coding Specifications
Clinical Context
A 67-year-old patient with progressive cytopenias and abnormal peripheral blood smear is referred to hematology. The hematologist orders molecular testing for SRSF2 mutations to evaluate for myelodysplastic syndrome (MDS) and to help stratify risk and guide therapy. A phlebotomy is performed in an outpatient laboratory or hospital phlebotomy service; whole blood or bone marrow aspirate is collected, labeled, and sent to a molecular diagnostics laboratory. The laboratory analyst performs a targeted molecular test for common SRSF2 variants (for example, P95H, P95L) using validated methods such as targeted next-generation sequencing or allele-specific PCR. Results are reported in the electronic medical record and communicated to the ordering clinician, who integrates the molecular result with bone marrow morphology, cytogenetics, and other molecular findings to establish a diagnosis and inform management decisions. Typical sites of service include hospital outpatient laboratories, independent commercial molecular diagnostic laboratories, and academic medical center molecular pathology labs.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When reporting only the professional interpretation component if separated from the technical testing |
TC |